{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T22:34:58Z","timestamp":1795127698399,"version":"4.10.3"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T00:00:00Z","timestamp":1684713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T00:00:00Z","timestamp":1684713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The emerging PET tracer [<jats:sup>68<\/jats:sup>Ga]Ga-PSMA-11 has been established for staging in prostate cancer (PCa). Aim was to determine the value of early static imaging in two-phase PET\/CT. 100 men with newly diagnosed histopathologically confirmed untreated PCa who underwent [<jats:sup>68<\/jats:sup>Ga]Ga-PSMA-11 PET\/CT from January 2017 to October 2019 were included. The two-phase imaging protocol consisted of an early static scan of the pelvis (6\u00a0min p.i.) and a late total-body scan (60\u00a0min p.i). Associations of semi-quantitative parameters derived via volumes of interest (VOI) with Gleason grade group and PSA were investigated. In 94\/100 patients (94%) the primary tumor was detected in both phases. In 29\/100 patients (29%) metastases were detected at a median PSA level of 32.2\u00a0ng\/ml (0.41\u2013503\u00a0ng\/ml). In 71\/100 patients (71%) without metastasis a median PSA level of 10.1\u00a0ng\/ml (0.57\u2013103\u00a0ng\/ml) was observed (<jats:italic>p<\/jats:italic>\u2009=\u2009&lt;\u20090.001). Primary tumors demonstrated a median standard uptake value maximum (SUVmax) of 8.2 (3.1\u201345.3) in early phase versus 12.2 (3.1\u201373.4) in late phase and a median standard uptake value mean (SUVmean) of 4.2 (1.6\u201324.1) in early phase versus 5.8 (1.6\u201339.9) in late phase, significantly increasing over time (<jats:italic>p<\/jats:italic>\u2009=\u2009&lt;\u20090.001). Higher SUVmax and SUVmean were associated with higher Gleason grade group (<jats:italic>p<\/jats:italic>\u2009=\u20090.004 and <jats:italic>p<\/jats:italic>\u2009=\u20090.003, respectively) and higher PSA levels (<jats:italic>p<\/jats:italic>\u2009=\u2009&lt;\u20090.001). In 13\/100 patients the semi-quantitative parameters including SUVmax were declining in the late phase compared to early phase. Two-phase [<jats:sup>68<\/jats:sup>Ga]Ga-PSMA-11 PET\/CT demonstrates a high detection rate for primary tumor of untreated PCa of 94% and improves diagnostic accuracy. Higher PSA levels and Gleason grade group are associated with higher semi-quantitative parameters in the primary tumor. Early imaging provides additional information in a small sub-group with declining semi-quantitative parameters in the late phase.<\/jats:p>","DOI":"10.1038\/s41598-023-35628-0","type":"journal-article","created":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T18:03:30Z","timestamp":1684778610000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Diagnostic value of two-time point [68Ga]Ga-PSMA-11 PET\/CT in the primary staging of untreated prostate cancer"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3230-8184","authenticated-orcid":false,"given":"Friedrich","family":"Weitzer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"Pernthaler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Plhak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina","family":"Riedl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reingard Maria","family":"Aigner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,22]]},"reference":[{"key":"35628_CR1","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1101\/gad.315739.118","volume":"32","author":"G Wang","year":"2018","unstructured":"Wang, G., Zhao, D., Spring, D. J. & Depinho, R. A. Genetics and biology of prostate cancer. Genes Dev. 32, 1105\u20131140 (2018).","journal-title":"Genes Dev."},{"key":"35628_CR2","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.physbeh.2017.03.040","volume":"46","author":"K Bouchelouche","year":"2016","unstructured":"Bouchelouche, K., Turkbey, B. & Choyke, P. L. PSMA PET and radionuclide therapy in prostate cancer. Semin. Nucl. Med. 46, 522\u2013535. https:\/\/doi.org\/10.1016\/j.physbeh.2017.03.040 (2016).","journal-title":"Semin. Nucl. Med."},{"key":"35628_CR3","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1097\/CCO.0000000000000277","volume":"28","author":"K Bouchelouche","year":"2016","unstructured":"Bouchelouche, K. & Choyke, P. L. PSMA PET in prostate cancer\u2014A step towards personalized medicine. Curr. Opin. Oncol. 28, 216\u2013221. https:\/\/doi.org\/10.1097\/CCO.0000000000000277 (2016).","journal-title":"Curr. Opin. Oncol."},{"key":"35628_CR4","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3390\/diagnostics8010016","volume":"8","author":"N Lenzo","year":"2018","unstructured":"Lenzo, N., Meyrick, D. & Turner, J. Review of Gallium-68 PSMA PET\/CT imaging in the management of prostate cancer. Diagnostics 8, 16. https:\/\/doi.org\/10.3390\/diagnostics8010016 (2018).","journal-title":"Diagnostics"},{"key":"35628_CR5","doi-asserted-by":"publisher","first-page":"70","DOI":"10.2967\/jnumed.119.229054","volume":"61","author":"JC dos Santos","year":"2020","unstructured":"dos Santos, J. C. et al. Development of novel PSMA ligands for imaging and therapy with copper isotopes. J. Nucl. Med. 61, 70\u201379. https:\/\/doi.org\/10.2967\/jnumed.119.229054 (2020).","journal-title":"J. Nucl. Med."},{"key":"35628_CR6","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s00259-019-04612-0","volume":"47","author":"F Khreish","year":"2020","unstructured":"Khreish, F. et al. 225Ac-PSMA-617\/177Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: Pilot experience. Eur. J. Nucl. Med. Mol. Imaging 47, 721\u2013728. https:\/\/doi.org\/10.1007\/s00259-019-04612-0 (2020).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"35628_CR7","doi-asserted-by":"publisher","first-page":"735","DOI":"10.2967\/jnumed.119.234922","volume":"61","author":"A Wurzer","year":"2020","unstructured":"Wurzer, A. et al. Radiohybrid ligands: A novel tracer concept exemplified by 18F- or 68Ga-labeled rhPSMA inhibitors. J. Nucl. Med. 61, 735\u2013742. https:\/\/doi.org\/10.2967\/jnumed.119.234922 (2020).","journal-title":"J. Nucl. Med."},{"key":"35628_CR8","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.2967\/jnumed.117.191031","volume":"58","author":"SM Schwarzenboeck","year":"2017","unstructured":"Schwarzenboeck, S. M. et al. PSMA ligands for PET imaging of prostate cancer. J. Nucl. Med. 58, 1545\u20131552. https:\/\/doi.org\/10.2967\/jnumed.117.191031 (2017).","journal-title":"J. Nucl. Med."},{"key":"35628_CR9","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.1007\/s00259-019-04485-3","volume":"46","author":"C Kratochwil","year":"2019","unstructured":"Kratochwil, C. et al. EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT). Eur. J. Nucl. Med. Mol. Imaging 46, 2536\u20132544. https:\/\/doi.org\/10.1007\/s00259-019-04485-3 (2019).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"35628_CR10","doi-asserted-by":"publisher","first-page":"200","DOI":"10.2174\/1874471011666180502104524","volume":"11","author":"A Morgenstern","year":"2018","unstructured":"Morgenstern, A. et al. An overview of targeted alpha therapy with 225Actinium and 213Bismuth. Curr. Radiopharm. 11, 200\u2013208. https:\/\/doi.org\/10.2174\/1874471011666180502104524 (2018).","journal-title":"Curr. Radiopharm."},{"key":"35628_CR11","doi-asserted-by":"publisher","first-page":"795","DOI":"10.2967\/jnumed.117.203539","volume":"59","author":"C Kratochwil","year":"2018","unstructured":"Kratochwil, C. et al. Targeted a-therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617: Swimmer-Plot Analysis Suggests efficacy regarding duration of tumor control. J. Nucl. Med. 59, 795\u2013802. https:\/\/doi.org\/10.2967\/jnumed.117.203539 (2018).","journal-title":"J. Nucl. Med."},{"key":"35628_CR12","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.eururo.2016.08.003","volume":"71","author":"N Mottet","year":"2017","unstructured":"Mottet, N. et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, diagnosis, and local treatment with curative intent. Eur. Urol. 71, 618\u2013629. https:\/\/doi.org\/10.1016\/j.eururo.2016.08.003 (2017).","journal-title":"Eur. Urol."},{"key":"35628_CR13","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.eururo.2020.09.046","volume":"79","author":"P Cornford","year":"2021","unstructured":"Cornford, P. et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II\u20142020 Update: Treatment of relapsing and metastatic prostate cancer [Formula presented]. Eur Urol 79, 263\u2013282 (2021).","journal-title":"Eur Urol"},{"key":"35628_CR14","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","volume":"79","author":"N Mottet","year":"2021","unstructured":"Mottet, N. et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer\u20142020 Update. Part 1: Screening, diagnosis, and local treatment with curative intent. Eur Urol 79, 243\u2013262 (2021).","journal-title":"Eur Urol"},{"key":"35628_CR15","unstructured":"Mottet, N., Cornford, P., van den Bergh, R. C. N., et al. EAU Guidelines. Edn. In Presented at the EAU Annual Congress Milan 2023. ISBN 978-94-92671-19-6."},{"key":"35628_CR16","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s40644-019-0273-x","volume":"19","author":"LA Rahman","year":"2019","unstructured":"Rahman, L. A. et al. High negative predictive value of 68Ga PSMA PET-CT for local lymph node metastases in high risk primary prostate cancer with histopathological correlation. Cancer Imaging 19, 86. https:\/\/doi.org\/10.1186\/s40644-019-0273-x (2019).","journal-title":"Cancer Imaging"},{"key":"35628_CR17","doi-asserted-by":"publisher","first-page":"82","DOI":"10.2967\/jnumed.117.197160","volume":"59","author":"PJ Roach","year":"2018","unstructured":"Roach, P. J. et al. The impact of 68Ga-PSMA PET\/CT on management intent in prostate cancer: Results of an australian prospective multicenter study. J. Nucl. Med. 59, 82\u201388. https:\/\/doi.org\/10.2967\/jnumed.117.197160 (2018).","journal-title":"J. Nucl. Med."},{"key":"35628_CR18","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1002\/jlcr.3227","volume":"57","author":"J Aerts","year":"2014","unstructured":"Aerts, J. et al. Guidance on current good radiopharmacy practice for the small-scale preparation of radiopharmaceuticals using automated modules: A European perspective. J. Label. Compd. Radiopharm. 57, 615\u2013620. https:\/\/doi.org\/10.1002\/jlcr.3227 (2014).","journal-title":"J. Label. Compd. Radiopharm."},{"key":"35628_CR19","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s00259-004-1708-5","volume":"32","author":"F Jacobs","year":"2005","unstructured":"Jacobs, F. et al. Optimised tracer-dependent dosage cards to obtain weight-independent effective doses. Eur. J. Nucl. Med. Mol. Imaging 32, 581\u2013588. https:\/\/doi.org\/10.1007\/s00259-004-1708-5 (2005).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"35628_CR20","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1007\/s00259-017-3725-1","volume":"44","author":"S Fanti","year":"2017","unstructured":"Fanti, S. et al. Development of standardized image interpretation for 68Ga-PSMA PET\/CT to detect prostate cancer recurrent lesions. Eur. J. Nucl. Med. Mol. Imaging 44, 1622\u20131635. https:\/\/doi.org\/10.1007\/s00259-017-3725-1 (2017).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"35628_CR21","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1001\/jama.280.11.969","volume":"280","author":"AV D\u2019Amico","year":"1998","unstructured":"D\u2019Amico, A. V. et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. J. Am. Med. Assoc. 280, 969\u2013974. https:\/\/doi.org\/10.1001\/jama.280.11.969 (1998).","journal-title":"J. Am. Med. Assoc."},{"key":"35628_CR22","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1007\/s002590100639","volume":"28","author":"M Hofmann","year":"2001","unstructured":"Hofmann, M. et al. Biokinetics and imaging with the somatostatin receptor PET radioligand 68Ga-DOTATOC: Preliminary data. Eur. J. Nucl. Med. 28, 1751\u20131757. https:\/\/doi.org\/10.1007\/s002590100639 (2001).","journal-title":"Eur. J. Nucl. Med."},{"key":"35628_CR23","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1007\/s00259-021-05659-8","volume":"49","author":"J Wen","year":"2022","unstructured":"Wen, J. et al. Determination of optimal 68Ga-PSMA PET\/CT imaging time in prostate cancers by total-body dynamic PET\/CT. Eur. J. Nucl. Med. Mol. Imaging 49, 2086\u20132095. https:\/\/doi.org\/10.1007\/s00259-021-05659-8 (2022).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"35628_CR24","doi-asserted-by":"publisher","first-page":"e473","DOI":"10.1097\/RLU.0000000000001349","volume":"41","author":"C Sachpekidis","year":"2016","unstructured":"Sachpekidis, C. et al. 68Ga-PSMA-11 dynamic PET\/CT imaging in primary prostate cancer. Clin. Nucl. Med. 41, e473\u2013e479. https:\/\/doi.org\/10.1097\/RLU.0000000000001349 (2016).","journal-title":"Clin. Nucl. Med."},{"key":"35628_CR25","first-page":"351","volume":"8","author":"C Sachpekidis","year":"2018","unstructured":"Sachpekidis, C. et al. 68Ga-PSMA-11 PET\/CT in prostate cancer local recurrence: Impact of early images and parametric analysis. Am. J. Nucl. Med. Mol. Imaging 8, 351\u2013359 (2018).","journal-title":"Am. J. Nucl. Med. Mol. Imaging"},{"key":"35628_CR26","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","volume":"395","author":"MS Hofman","year":"2020","unstructured":"Hofman, M. S. et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): A prospective, randomised, multicentre study. Lancet 395, 1208\u20131216. https:\/\/doi.org\/10.1016\/S0140-6736(20)30314-7 (2020).","journal-title":"Lancet"},{"key":"35628_CR27","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1007\/s00259-017-3631-6","volume":"44","author":"C Uprimny","year":"2017","unstructured":"Uprimny, C. et al. 68Ga-PSMA-11 PET\/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour. Eur. J. Nucl. Med. Mol. Imaging 44, 941\u2013949. https:\/\/doi.org\/10.1007\/s00259-017-3631-6 (2017).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"35628_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers12102788","volume":"12","author":"MA Hoffmann","year":"2020","unstructured":"Hoffmann, M. A. et al. Dual-time point [68Ga]Ga-Psma-11 PET\/CT hybrid imaging for staging and restaging of prostate cancer. Cancers (Basel) 12, 1\u201315. https:\/\/doi.org\/10.3390\/cancers12102788 (2020).","journal-title":"Cancers (Basel)"},{"key":"35628_CR29","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-023-09516-0","author":"M Bauckneht","year":"2023","unstructured":"Bauckneht, M. et al. Combined forced diuresis and late acquisition on [68Ga]Ga-PSMA-11 PET\/CT for biochemical recurrent prostate cancer: A clinical practice-oriented study. Eur. Radiol. https:\/\/doi.org\/10.1007\/s00330-023-09516-0 (2023).","journal-title":"Eur. Radiol."},{"key":"35628_CR30","doi-asserted-by":"publisher","first-page":"449","DOI":"10.21873\/anticanres.16181","volume":"43","author":"J Ferda","year":"2023","unstructured":"Ferda, J. et al. Assessment of prostate carcinoma aggressiveness: Relation to 68Ga-PSMA-11-PET\/MRI and Gleason score. Anticancer Res. 43, 449\u2013453. https:\/\/doi.org\/10.21873\/anticanres.16181 (2023).","journal-title":"Anticancer Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-35628-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-35628-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-35628-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T06:08:11Z","timestamp":1684822091000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-35628-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,22]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["35628"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-35628-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,22]]},"assertion":[{"value":"4 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8297"}}